CA3189147A1 - Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists - Google Patents

Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists

Info

Publication number
CA3189147A1
CA3189147A1 CA3189147A CA3189147A CA3189147A1 CA 3189147 A1 CA3189147 A1 CA 3189147A1 CA 3189147 A CA3189147 A CA 3189147A CA 3189147 A CA3189147 A CA 3189147A CA 3189147 A1 CA3189147 A1 CA 3189147A1
Authority
CA
Canada
Prior art keywords
activin
antibody
antigen
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3189147A
Other languages
English (en)
French (fr)
Inventor
David Glass
Scott MACDONNELL
Jake MEGNA
Lori MORTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3189147A1 publication Critical patent/CA3189147A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3189147A 2020-08-20 2021-08-19 Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists Pending CA3189147A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063068251P 2020-08-20 2020-08-20
US63/068,251 2020-08-20
US202063111394P 2020-11-09 2020-11-09
US63/111,394 2020-11-09
US202163139234P 2021-01-19 2021-01-19
US63/139,234 2021-01-19
PCT/US2021/046765 WO2022040461A1 (en) 2020-08-20 2021-08-19 Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists

Publications (1)

Publication Number Publication Date
CA3189147A1 true CA3189147A1 (en) 2022-02-24

Family

ID=77774983

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3189147A Pending CA3189147A1 (en) 2020-08-20 2021-08-19 Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists

Country Status (10)

Country Link
US (2) US20220056119A1 (https=)
EP (1) EP4200017A1 (https=)
JP (1) JP2023539107A (https=)
KR (1) KR20230051683A (https=)
CN (1) CN116249713A (https=)
AU (1) AU2021327238A1 (https=)
CA (1) CA3189147A1 (https=)
IL (1) IL300362A (https=)
MX (1) MX2023001734A (https=)
WO (1) WO2022040461A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
JP5766179B2 (ja) 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
PT3286206T (pt) * 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
WO2018009732A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
CA3052625A1 (en) * 2017-02-06 2018-08-09 Acceleron Pharma Inc. Compositions and methods for treating heart failure
FI3600415T3 (fi) * 2017-03-24 2025-12-05 Novartis Ag Aktiviinireseptorin tyypin ii reseptorin vastainen vasta-aine käytettäväksi sydämen vajaatoiminnan hoidossa
WO2019005963A1 (en) * 2017-06-27 2019-01-03 The University Of Chicago USE OF ACTIVIN TO DETECT POST-PARTUM CARDIAC DYSFUNCTION

Also Published As

Publication number Publication date
CN116249713A (zh) 2023-06-09
MX2023001734A (es) 2023-03-31
AU2021327238A9 (en) 2024-06-06
US20220056119A1 (en) 2022-02-24
WO2022040461A1 (en) 2022-02-24
IL300362A (en) 2023-04-01
US20250277021A1 (en) 2025-09-04
KR20230051683A (ko) 2023-04-18
JP2023539107A (ja) 2023-09-13
AU2021327238A1 (en) 2023-04-27
EP4200017A1 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
JP7141333B2 (ja) 抗－ａｎｇｐｔｌ８抗体及びその使用
JP6829199B2 (ja) エボラウイルス糖タンパク質に対するヒト抗体
JP6581085B2 (ja) 抗アクチビンａ抗体及びその使用
US20180008672A1 (en) Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
US10519240B2 (en) Anti-FGFR1c antibody-FGF21 fusion proteins
CA2960763A1 (en) Anti-glucagon antibodies and uses thereof
US11066474B2 (en) Anti-TrkB monoclonal antibodies and methods of use
US12325752B2 (en) Immunoglobulin proteins that bind to NPR1 agonists
US20180057580A1 (en) Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension
US20250277021A1 (en) Methods for Preventing and Treating Cardiac Dysfunction and COVID-19 with Activin A Antagonists
US12030935B2 (en) Anti-PDGF-B antibodies and pharmaceutical composition thereof
JP7807238B2 (ja) 骨形成タンパク質６に対するヒト抗体
US12612452B2 (en) Human antibodies to bone morphogenetic protein 6
KR20240099304A (ko) 인자 xi a2 도메인 결합 항체 및 이의 사용 방법
HK1233666B (en) Fgf21 receptor agonists and uses thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250724

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250818

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250818

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250818

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250821